These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 15654945)

  • 1. Breaking tolerance--another piece added to the vitiligo puzzle.
    Lee DJ; Modlin RL
    J Invest Dermatol; 2005 Jan; 124(1):xiii-xv. PubMed ID: 15654945
    [No Abstract]   [Full Text] [Related]  

  • 2. Peripheral CD8+ T cell tolerance against melanocytic self-antigens in the skin is regulated in two steps by CD4+ T cells and local inflammation: implications for the pathophysiology of vitiligo.
    Steitz J; Brück J; Lenz J; Büchs S; Tüting T
    J Invest Dermatol; 2005 Jan; 124(1):144-50. PubMed ID: 15654968
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Initiation and regulation of CD8+T cells recognizing melanocytic antigens in the epidermis: implications for the pathophysiology of vitiligo.
    Steitz J; Wenzel J; Gaffal E; Tüting T
    Eur J Cell Biol; 2004 Dec; 83(11-12):797-803. PubMed ID: 15679123
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Maintenance of immune hyporesponsiveness to melanosomal proteins by DHICA-mediated antioxidation: Possible implications for autoimmune vitiligo.
    Liu XM; Zhou Q; Xu SZ; Wakamatsu K; Lei TC
    Free Radic Biol Med; 2011 May; 50(9):1177-85. PubMed ID: 21256957
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Absence of tyrosinase-related protein-2/dopachrome tautomerase transcripts in PBMCs from vitiligo patients.
    Bam M; Bagchi T
    Scand J Immunol; 2009 Apr; 69(4):366-73. PubMed ID: 19284502
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune mechanisms in vitiligo.
    Bystryn JC
    Immunol Ser; 1989; 46():447-73. PubMed ID: 2488866
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Possible roles of B lymphocyte activating factor of the tumour necrosis factor family in vitiligo autoimmunity.
    Lin X; Tian H; Xianmin M
    Med Hypotheses; 2011 Mar; 76(3):339-42. PubMed ID: 21075543
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vitiligo and antibodies to melanocytes.
    Bystryn JC; Pfeffer S
    Prog Clin Biol Res; 1988; 256():195-206. PubMed ID: 3285350
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Unraveling the complex relationship between cancer immunity and autoimmunity: lessons from melanoma and vitiligo.
    Uchi H; Stan R; Turk MJ; Engelhorn ME; Rizzuto GA; Goldberg SM; Wolchok JD; Houghton AN
    Adv Immunol; 2006; 90():215-41. PubMed ID: 16730265
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vitiligo and juvenile diabetes mellitus.
    Macaron C; Winter RJ; Traisman HS; Kahan BD; Lasser AE; Green OC
    Arch Dermatol; 1977 Nov; 113(11):1515-7. PubMed ID: 931387
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Physiopathology and genetics of vitiligo.
    Passeron T; Ortonne JP
    J Autoimmun; 2005; 25 Suppl():63-8. PubMed ID: 16298511
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vitiligo: auto-immunity and immune responses.
    Sehgal VN; Srivastava G
    Int J Dermatol; 2006 May; 45(5):583-90. PubMed ID: 16700798
    [No Abstract]   [Full Text] [Related]  

  • 13. Autoimmunity as an aetiological factor in vitiligo.
    Rezaei N; Gavalas NG; Weetman AP; Kemp EH
    J Eur Acad Dermatol Venereol; 2007 Aug; 21(7):865-76. PubMed ID: 17658994
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current remedies for vitiligo.
    Abu Tahir M; Pramod K; Ansari SH; Ali J
    Autoimmun Rev; 2010 May; 9(7):516-20. PubMed ID: 20149899
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Abnormal expression of MHC class II and ICAM-1 by melanocytes in vitiligo.
    al Badri AM; Foulis AK; Todd PM; Gariouch JJ; Gudgeon JE; Stewart DG; Gracie JA; Goudie RB
    J Pathol; 1993 Feb; 169(2):203-6. PubMed ID: 8095298
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Immunological changes in common vitiligo].
    Vignale R; Paciel J; Calandria L
    Med Cutan Ibero Lat Am; 1988; 16(4):343-7. PubMed ID: 3068448
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Specific cytotoxic T lymphocyte responses against Melan-A/MART1, tyrosinase and gp100 in vitiligo by the use of major histocompatibility complex/peptide tetramers: the role of cellular immunity in the etiopathogenesis of vitiligo.
    Palermo B; Campanelli R; Garbelli S; Mantovani S; Lantelme E; Brazzelli V; Ardigó M; Borroni G; Martinetti M; Badulli C; Necker A; Giachino C
    J Invest Dermatol; 2001 Aug; 117(2):326-32. PubMed ID: 11511311
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum levels of functional T-regs in vitiligo: our experience and mini-review of the literature.
    Richetta A; D'Epiro S; Salvi M; Campoli M; Giancristoforo S; Mattozzi C; Macaluso L; Luci C; Cantisani C; Carboni V; Zanniello R; Zampetti M; Milana B; Morrone S; Calvieri S
    Eur J Dermatol; 2013 Apr; 23(2):154-9. PubMed ID: 23608724
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunological basis of melanoma-associated vitiligo-like depigmentation.
    González R; Torres-López E
    Actas Dermosifiliogr; 2014 Mar; 105(2):122-7. PubMed ID: 23146137
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of interleukin-17 in the pathogenesis of vitiligo.
    Bassiouny DA; Shaker O
    Clin Exp Dermatol; 2011 Apr; 36(3):292-7. PubMed ID: 21198791
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.